Is Ipamorelin FDA-Approved? Regulatory Status

The short version

Is ipamorelin FDA approved? No. Ipamorelin has never been approved as a medicine by the FDA or any other regulator, for any condition ^[3]. It was tested in people exactly once in a published trial — after bowel surgery — and it did not work ^[3]. In 2024 the FDA also took it off the list of substances that compounding pharmacies were allowed to use, which narrowed legal access further ^[3]. On top of that, it is banned in sports at all times ^[7]. So when a website calls ipamorelin "medicinal" or "pharmaceutical-grade," that is marketing language, not a regulatory status — it describes how a powder is made, not any approval to use it in humans. Everything below is the paper trail behind those statements, with each fact tied to a source you can check.

No approval, anywhere

Ipamorelin holds no marketing approval from the FDA, the European Medicines Agency, or any comparable authority ^[3]. It has no approved indication, no approved label, and no approved dose. This is not a case of a drug still working its way through review — the only clinical program that reached Phase 2 ended without success, so the absence of approval reflects a failed efficacy program rather than incomplete paperwork ^[3].

That distinction matters for readers trying to interpret marketing claims. "Research-grade," "pharmaceutical-grade," and "99% pure" are descriptions of a manufactured powder. None of them is a statement that a regulator has reviewed ipamorelin and found it safe and effective for a human use. No such review has ever concluded in ipamorelin's favor.

The one human trial — and why it ended

Ipamorelin's single published human efficacy trial tested it for postoperative ileus, the temporary shutdown of bowel movement that follows abdominal surgery (NCT00672074). The study enrolled 114 adults undergoing bowel resection, who received 0.03 mg/kg intravenously twice daily for up to seven days ^[3].

It missed its primary endpoint. Median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo — numerically faster, but not statistically significant (p=0.15) ^[3]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo, so the trial surfaced no ipamorelin-specific safety alarm in that short window — but it also did not demonstrate that the drug worked ^[3]. No Phase 3 trial followed, and the indication was not pursued.

What changed in 2024: the 503A decision

For several years, ipamorelin acetate sat in Category 2 of the FDA's interim list of bulk drug substances eligible for pharmacy compounding under Section 503A. In 2024 that changed. Following the nominator's withdrawal in September 2024, the FDA removed ipamorelin acetate from Category 2, and both the acetate and free-base forms were reviewed at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting ^[3].

The practical consequence: ipamorelin is not an approved bulk substance for compounding. A reader should not infer from the word "medicinal," or from a clinic's website, that ipamorelin is eligible for legitimate compounding-pharmacy preparation. The 2024 action moved in the opposite direction — toward restricting that access, not granting it ^[3].

Banned in sport, and detectable

Ipamorelin is prohibited in sport at all times under the World Anti-Doping Agency (WADA) Prohibited List, category S2 (peptide hormones, growth factors, and mimetics) ^[7]. The prohibition is not theoretical: accredited anti-doping laboratories have validated several methods to detect it in urine.

A direct-urine-injection ion-mobility mass-spectrometry method screens ipamorelin alongside 17 other prohibited small peptides at detection limits of 50–500 pg/mL ^[7]. An earlier high-resolution method reached 2–10 pg/mL for a panel including ipamorelin ^[8], and a validated assay covering ipamorelin and seven other GH-releasing peptides worked at 0.2–1 ng/mL while also flagging previously unknown metabolites ^[9]. For any tested athlete, ipamorelin is both banned and findable.